Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) – a randomized controlled trial

Proportion of patients achieving at least 75% reduction in hand eczema severity index (HECSI75) at week 16 when compared to HECSI at baseline. HECSI is a measure of hand eczema disease severity considering the extent and intensity of the disease. The score reflects HE severity as following: 1-16, mild HE; 17-37, moderate HE; 38-116 severe HE and 117-360, very severe HE.